{"paper_id":"08ada0e4-d3e4-4142-bfaf-42ce13851803","body_text":"Print ISSN: 1019-6439\nOnline ISSN: 1791-2423\nInternational Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.\nInternational Journal of Oncology is an international journal devoted to oncology research and cancer treatment.\nCovers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.\nOncology Reports is an international journal devoted to fundamental and applied research in Oncology.\nExperimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.\nOncology Letters is an international journal devoted to Experimental and Clinical Oncology.\nExplores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.\nInternational journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.\nMultidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.\nOpen-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.\nPublishes open-access research on using epigenetics to advance understanding and treatment of human disease.\nAn International Open Access Journal Devoted to General Medicine.\nReview\nOpen Access\n- Authors:\n-\nPages: 1755-1762|Published online on: February 21, 2012https://doi.org/10.3892/ijo.2012.1384\n- Expand metrics +\nProgestin preparations are made of synthetic progesterone and have often been used for hormone therapy in gynecological patients with endometriosis or endometrial cancer. Hormone therapy using progestin is considered to be one of the effective means of treatment particularly when dealing with endometrial cancer (an estrogen-dependent tumor). Numerous reports have been published concerning its efficacy in advanced or recurrent cases of atypical endometrial hyperplasia or endometrial cancer. Dienogest has been developed as a fourth-generation progestin for hormone therapy for endometriosis that can be used with high safety for long periods of time. In Japan, dienogest has been recommended as a first-line drug for endometriosis-associated pain. However, its antitumor activity has also been attracting close attention following a report that this drug suppressed the proliferation in vitro of endometrial cancer-derived cell lines which failed to respond to other progestins such as medroxyprogesterine acetate (MPA). The mechanism for antitumor activity of dienogest is considered to differ from the mechanism for antitumor activity of conventional progestin preparations used for treatment of endometrial cancer. This drug is expected to be clinically applicable as a new drug for the treatment of endometrial cancer.\nCopy and paste a formatted citation\nSpandidos Publications style\nBanno K, Kisu I, Yanokura M, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, Nomura H, Susumu N, Susumu N, et al: Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review). Int J Oncol 40: 1755-1762, 2012.\nAPA\nBanno, K., Kisu, I., Yanokura, M., Tsuji, K., Masuda, K., Ueki, A. ... Aoki, D. (2012). Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review). International Journal of Oncology, 40, 1755-1762. https://doi.org/10.3892/ijo.2012.1384\nMLA\nBanno, K., Kisu, I., Yanokura, M., Tsuji, K., Masuda, K., Ueki, A., Kobayashi, Y., Yamagami, W., Nomura, H., Susumu, N., Aoki, D.\"Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)\". International Journal of Oncology 40.6 (2012): 1755-1762.\nChicago\nBanno, K., Kisu, I., Yanokura, M., Tsuji, K., Masuda, K., Ueki, A., Kobayashi, Y., Yamagami, W., Nomura, H., Susumu, N., Aoki, D.\"Progestin therapy for endometrial cancer: The potential of fourth-generation progestin (Review)\". International Journal of Oncology 40, no. 6 (2012): 1755-1762. https://doi.org/10.3892/ijo.2012.1384","source_license":"CC0","license_restricted":false}